PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
153.33%
Revenue growth exceeding 1.5x TRVN's 100.00%. David Dodd would verify if faster growth reflects superior business model.
-27.15%
Both companies reducing costs. Martin Whitman would check industry efficiency trends.
73.30%
Similar gross profit growth to TRVN's 91.87%. Walter Schloss would investigate industry dynamics.
89.46%
Margin expansion while TRVN shows decline. John Neff would investigate competitive advantages.
8.30%
R&D growth while TRVN reduces spending. John Neff would investigate strategic advantage.
28.80%
G&A change of 28.80% while TRVN maintains overhead. Bruce Berkowitz would investigate efficiency.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
14.70%
Operating expenses growth while TRVN reduces costs. John Neff would investigate differences.
14.70%
Total costs growth while TRVN reduces costs. John Neff would investigate differences.
-100.00%
Interest expense reduction while TRVN shows 32.17% growth. Joel Greenblatt would examine advantage.
-27.15%
Both companies reducing D&A. Martin Whitman would check industry patterns.
-16.20%
EBITDA decline while TRVN shows 39.59% growth. Joel Greenblatt would examine position.
54.13%
EBITDA margin growth while TRVN declines. John Neff would investigate advantages.
-15.23%
Operating income decline while TRVN shows 40.67% growth. Joel Greenblatt would examine position.
54.52%
Operating margin growth while TRVN declines. John Neff would investigate advantages.
98.15%
Other expenses growth less than half of TRVN's 409.13%. David Dodd would verify if advantage is sustainable.
-12.38%
Pre-tax income decline while TRVN shows 54.20% growth. Joel Greenblatt would examine position.
55.64%
Pre-tax margin growth while TRVN declines. John Neff would investigate advantages.
-98.15%
Tax expense reduction while TRVN shows 199.41% growth. Joel Greenblatt would examine advantage.
-9.33%
Net income decline while TRVN shows 49.70% growth. Joel Greenblatt would examine position.
56.84%
Net margin growth while TRVN declines. John Neff would investigate advantages.
-5.41%
EPS decline while TRVN shows 4.61% growth. Joel Greenblatt would examine position.
-8.33%
Diluted EPS decline while TRVN shows 4.61% growth. Joel Greenblatt would examine position.
2.98%
Share count increase while TRVN reduces shares. John Neff would investigate differences.
2.03%
Diluted share increase while TRVN reduces shares. John Neff would investigate differences.